Login to Your Account


Clinic Roundup


Tuesday, January 25, 2011
Raptor Pharmaceutical Corp., of Novato, Calif., completed enrollment in a Phase III study of its delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics